MA34384B1 - Composés hétérocycliques, leur préparation et leur application thérapeutique - Google Patents

Composés hétérocycliques, leur préparation et leur application thérapeutique

Info

Publication number
MA34384B1
MA34384B1 MA35572A MA35572A MA34384B1 MA 34384 B1 MA34384 B1 MA 34384B1 MA 35572 A MA35572 A MA 35572A MA 35572 A MA35572 A MA 35572A MA 34384 B1 MA34384 B1 MA 34384B1
Authority
MA
Morocco
Prior art keywords
preparation
heterocyclic compounds
therapeutic application
methods
ameliorating
Prior art date
Application number
MA35572A
Other languages
English (en)
Inventor
David Middlemiss
Caroline Leriche
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of MA34384B1 publication Critical patent/MA34384B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne certains nouveaux composés, des procédés de production de ceux-ci et des méthodes de traitement ou d'amélioration d'un trouble médié par une kinase.
MA35572A 2010-06-22 2011-06-22 Composés hétérocycliques, leur préparation et leur application thérapeutique MA34384B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305665 2010-06-22
PCT/EP2011/060445 WO2011161159A1 (fr) 2010-06-22 2011-06-22 Composés hétérocycliques, leur préparation et leur application thérapeutique

Publications (1)

Publication Number Publication Date
MA34384B1 true MA34384B1 (fr) 2013-07-03

Family

ID=43033247

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35572A MA34384B1 (fr) 2010-06-22 2011-06-22 Composés hétérocycliques, leur préparation et leur application thérapeutique

Country Status (28)

Country Link
US (1) US20130123271A1 (fr)
EP (1) EP2585439A1 (fr)
JP (1) JP2013533237A (fr)
KR (1) KR20130116070A (fr)
CN (1) CN103140480A (fr)
AR (1) AR081960A1 (fr)
AU (1) AU2011268938A1 (fr)
BR (1) BR112012032721A2 (fr)
CA (1) CA2803496A1 (fr)
CL (1) CL2012003637A1 (fr)
CO (1) CO6660505A2 (fr)
CR (1) CR20120653A (fr)
DO (1) DOP2012000317A (fr)
EA (1) EA201291329A1 (fr)
EC (1) ECSP12012354A (fr)
GT (1) GT201200345A (fr)
IL (1) IL223721A0 (fr)
MA (1) MA34384B1 (fr)
MX (1) MX2012015305A (fr)
NI (1) NI201200193A (fr)
NZ (1) NZ605022A (fr)
PE (1) PE20130640A1 (fr)
PH (1) PH12012502525A1 (fr)
SG (1) SG186424A1 (fr)
TN (1) TN2012000610A1 (fr)
TW (1) TW201204723A (fr)
UY (1) UY33461A (fr)
WO (1) WO2011161159A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343294A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
HK1222849A1 (zh) * 2013-06-07 2017-07-14 Bayer Pharma Aktiengesellschaft 具有作爲mps-1抑制剂的活性的取代的三唑并吡啶类
HK1219737A1 (zh) * 2013-06-10 2017-04-13 Bayer Pharma Aktiengesellschaft 用於治疗癌症的新化合物
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
EP3390387B1 (fr) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Composés hétéroarylbenzimidazole
WO2017176981A1 (fr) * 2016-04-08 2017-10-12 Baylor College Of Medicine Régulateurs à petites molécules de coactivateurs des récepteurs stéroïdiens et méthodes d'utilisation de ceux-ci
WO2017207534A1 (fr) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Composés hétéroarylbenzimidazole substitués
WO2018213219A1 (fr) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones et composés apparentés utilisés en tant qu'inhibiteurs de protéine kinases
CN115916759B (zh) * 2020-06-19 2025-07-15 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
EP0163696B1 (fr) 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Application d'une bioadhesive
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
EP1235815A1 (fr) 1999-11-22 2002-09-04 Warner-Lambert Company Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US7691866B2 (en) 2003-10-16 2010-04-06 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
EP2543376A1 (fr) 2004-04-08 2013-01-09 Targegen, Inc. Inhibiteurs de benzotriazine de kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
JP2008533166A (ja) 2005-03-16 2008-08-21 ターゲジェン インコーポレーティッド ピリミジン化合物および使用法
US7906522B2 (en) * 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
AU2006254825A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US20100216791A1 (en) 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JP2010514693A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JPWO2009084695A1 (ja) 2007-12-28 2011-05-19 カルナバイオサイエンス株式会社 ２−アミノキナゾリン誘導体
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
CA2748319A1 (fr) 2008-12-29 2010-07-08 Fovea Pharmaceuticals Composes quinazoline substitues de formule generale (i) et leurs utilisations pour le traitement de troubles relatifs au dereglement entraine par une tyrosine kinase
SG173610A1 (en) * 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors

Also Published As

Publication number Publication date
CN103140480A (zh) 2013-06-05
PE20130640A1 (es) 2013-03-30
US20130123271A1 (en) 2013-05-16
EP2585439A1 (fr) 2013-05-01
CL2012003637A1 (es) 2013-07-05
JP2013533237A (ja) 2013-08-22
IL223721A0 (en) 2013-03-05
PH12012502525A1 (en) 2014-02-10
CA2803496A1 (fr) 2011-12-29
UY33461A (es) 2012-01-31
TN2012000610A1 (en) 2014-04-01
DOP2012000317A (es) 2013-04-15
CO6660505A2 (es) 2013-04-30
GT201200345A (es) 2014-01-24
BR112012032721A2 (pt) 2016-11-29
AU2011268938A1 (en) 2013-01-24
ECSP12012354A (es) 2013-01-31
SG186424A1 (en) 2013-01-30
KR20130116070A (ko) 2013-10-22
EA201291329A1 (ru) 2013-05-30
AR081960A1 (es) 2012-10-31
MX2012015305A (es) 2013-05-30
TW201204723A (en) 2012-02-01
CR20120653A (es) 2013-04-03
NZ605022A (en) 2013-12-20
NI201200193A (es) 2013-05-13
WO2011161159A1 (fr) 2011-12-29

Similar Documents

Publication Publication Date Title
MA34384B1 (fr) Composés hétérocycliques, leur préparation et leur application thérapeutique
PH12016500531A1 (en) Compound inhibiting activities of btk and/or jak3 kinases
EA201071057A1 (ru) Производные азетидина и циклобутана как ингибиторы jak-киназ
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MA34235B1 (fr) Composes chimiques
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
MA37477A1 (fr) Modulateurs des voies du complément et leurs utilisations
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
JO3316B1 (ar) مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
SG194728A1 (en) Inhibitors of bruton's tyrosine kinase
PH12014500128A1 (en) Inhibitors of bruton's tyrosine kinase
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
IN2014MN02082A (fr)
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MA37999B1 (fr) Dérivés de macrolide, leur préparation et leur utilisation thérapeutique
MA38636A1 (fr) Composés de 3,4-dihydroisoquinoléin-2(1h)-yle
EA201890558A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
UA110108C2 (xx) Азетидинові похідні піперидин-4-ілу як інгібітори jak1